^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vanflyta (quizartinib) (FLT3 inhibitor) + IMGN779 (DNA replication inhibitor, CD33-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ROBUST IN VIVO SYNERGY BETWEEN THE ANTI-CD33 ADC, IMGN779 AND THE FLT3 INHIBITOR QUIZARTINIB IN HUMAN FLT3-ITD AML MODELS.
Published date:
05/17/2018
Excerpt:
The in vitro combination of IMGN779 and quizartinib in both FLT3-ITD-positive cell lines led to dose-dependent additive or synergistic anti-leukemic activity…
